Magnetar Financial’s ADC Therapeutics ADCT Stock Holding History

Magnetar Financial’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.8K	Hold	39,092	–	–	﹤0.01%	1111
2026 Q1	$147K	Hold	39,092	–	–	﹤0.01%	946
2025 Q4	$138K	Hold	39,092	–	–	﹤0.01%	831
2025 Q3	$156K	Hold	39,092	–	–	﹤0.01%	793
2025 Q2	$105K	Sell	39,092 -16,670	-30%	-$35.1K	﹤0.01%	839
2025 Q1	$78.6K	Hold	55,762	–	–	﹤0.01%	708
2024 Q4	$111K	Hold	55,762	–	–	﹤0.01%	574
2024 Q3	$176K	Hold	55,762	–	–	﹤0.01%	479
2024 Q2	$176K	Hold	55,762	–	–	﹤0.01%	469
2024 Q1	$250K	Hold	55,762	–	–	0.01%	335
2023 Q4	$92.6K	Hold	55,762	–	–	﹤0.01%	344
2023 Q3	$50K	Hold	55,762	–	–	﹤0.01%	422
2023 Q2	$120K	Hold	55,762	–	–	﹤0.01%	442
2023 Q1	$109K	Sell	55,762 -71,106	-56%	-$262K	﹤0.01%	560
2022 Q4	$487K	Sell	126,868 -40,000	-24%	-$160K	0.01%	607
2022 Q3	$804K	Sell	166,868 -830	-0.5%	-$6.01K	0.01%	754
2022 Q2	$1.33M	Hold	167,698	–	–	0.01%	870
2022 Q1	$2.46M	Buy	167,698 +40,000	+31%	+$635K	0.03%	620
2021 Q4	$2.58M	Buy	127,698 +2,500	+2%	+$60.3K	0.03%	620
2021 Q3	$3.4M	Sell	125,198 -15,000	-11%	-$384K	0.03%	487
2021 Q2	$3.41M	Buy	140,198 +30,000	+27%	+$696K	0.03%	489
2021 Q1	$2.69M	Hold	110,198	–	–	0.03%	508
2020 Q4	$3.53M	Sell	110,198 -1,513,012	-93%	-$49.6M	0.05%	277
2020 Q3	$49.4M	Buy	1,623,210 +59,772	+4%	+$2.59M	0.87%	23
2020 Q2	$64.4M	Buy	+1,563,438	New	+$59.3M	1.9%	15

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Magnetar Financial's ADCT Position: Q2 2026 in Review

Magnetar Financial held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 39,092 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

Magnetar Financial first reported a position in ADCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $64.4M in Q2 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Magnetar Financial held 39,092 shares of ADC Therapeutics worth $41.8K as of Q2 2026.
Magnetar Financial left its ADC Therapeutics share count unchanged in Q2 2026.
ADC Therapeutics made up ﹤0.01% of Magnetar Financial's portfolio in Q2 2026, its #1111 holding.
Magnetar Financial first reported a position in ADC Therapeutics in Q2 2020 and has held it in 25 quarters since.
Magnetar Financial's ADC Therapeutics position peaked at $64.4M in Q2 2020.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.